Dear All, I promise that the next email will be all about the 25 Mar 2020 NHS England webinar on their antibiotic evaluation and procurement pilot (you’re going to love it … NICE and NHS England are doing great stuff … go here if you want to see a prior newsletter on this topic), BUT
Dear All, Sharpen your pencils! The Novo REPAIR Impact Fund has just opened its 2020 call for proposals. The focus is on: Pathogens: from the high-priority list of the World Health Organization and the United States Centers for Disease Control and Prevention Therapies: first-in-class therapies have priority Modalities: small molecules, biologics and new modalities Phases: from the
Dear All: As you know, WHO produced a pipeline update with a cut-off date of 1 July 2018. It’s now published both as a manuscript (Theuretzbacher et al. Lancet ID 2018, link) and a set of summary tables (link). Team WHO would like to update this analysis with a cut-off date of 1 Aug 2019. They
Dear All, Two important new research calls are now out. First, FDA is offering research funding of up to $1m to support creation of rabbit models of ventilator-associated bacterial pneumonia (VAP or VABP, depending on your preferred abbreviation) due to carbapenem-resistant strains of A. baumannii and P. aeruginosa. The call for proposals is via FDA Broad Agency Announcement (FDABAA-20-00123N, link), an ongoing
Dear All: The new Novo REPAIR impact fund ($165m over 5 years for antibacterials) is now open for applications — see the template at this link. Applications are due 15 May. Relatedly, Novo would like to hire a Senior Associate to help manage the fund. Primary qualifications are (1) scientific understanding of microbiology or a related
Dear All: I’ve written before about BARDA’s DRIVe initiative (Division of Research Innovation and Ventures, launched June 2018) that seeks to develop countermeasures for chemical, biological, radiological, and nuclear threats, as well as for pandemic influenza and emerging infectious diseases. As a core part of this work, DRIVe Ventures seeks to link innovators and investors through creation of a VC-like
Dear All: I trust you are now home after ECCMID in Madrid … it was an excellent meeting. Two new funding opportunities have recently crossed my radar: brief summaries and one key link for each are here with some further details below my signature. EU JPIAMR funding call: As part of its Virtual Research Institute
Dear All: Yes, I know that yesterday’s Scary/Scarier/Scariest newsletter about Achaogen was a downer. That note was as hard to write as I’m sure it was to read! I’ve received multiple comments and questions regarding the path forward and you can expect a follow-up note on this in the near future. For today, an initial way to act for
Dear All: Two things today. First, Ursula Theuretzbacher, Miloje Savic, Christine Ardal, and Kevin Outterson have published in Nature Reviews Drug Discovery a brief but instructive snapshot of the global preclinical antibacterial pipeline. This report nicely complements the recent WHO analysis of the clinical pipeline that concluded that “the world is running out of antibiotics.” You’ll want to read the paper yourself (it’s
Also note several new webinars in the forward meeting list! Dear All: NIAID currently has an open BAA (Broad Agency Announcement, HHS-NIH-NIAID-BAA2019-1, link), that calls for proposals across three research areas: Medical Countermeasures (MCMs), therapeutics for resistant bacteria, and vaccines for resistant bacteria. The deadline for Research Area 001 (MCMs) is still 20 May 2019, but the
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust